CareDx, Inc. (CDNA) Insider James P. Yee Sells 29,197 Shares of Stock
CareDx, Inc. (NASDAQ:CDNA) insider James P. Yee sold 29,197 shares of the company’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $7.00, for a total transaction of $204,379.00. Following the completion of the transaction, the insider now owns 74,795 shares in the company, valued at $523,565. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of CareDx, Inc. (NASDAQ CDNA) traded up $0.58 on Friday, hitting $7.18. 222,262 shares of the stock traded hands, compared to its average volume of 305,315. CareDx, Inc. has a 52-week low of $0.76 and a 52-week high of $7.98. The company has a debt-to-equity ratio of -124.53, a current ratio of 0.55 and a quick ratio of 0.35.
CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.02. CareDx had a negative net margin of 84.14% and a negative return on equity of 157.00%. The firm had revenue of $12.19 million during the quarter, compared to analysts’ expectations of $12.05 million. The company’s revenue was down 2.3% compared to the same quarter last year. equities analysts expect that CareDx, Inc. will post -0.83 EPS for the current year.
CDNA has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of CareDx from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Craig Hallum restated a “buy” rating and issued a $10.00 target price (up from $4.00) on shares of CareDx in a research note on Monday, October 9th. Raymond James Financial raised shares of CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price target for the company in a research report on Wednesday, September 27th. ValuEngine raised shares of CareDx from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $7.00 price target (up previously from $3.00) on shares of CareDx in a research report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $7.75.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Stock Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related stocks with our FREE daily email newsletter.